生命科学资讯
生物技术与制药领域的最新动态
Novo's threat to sue Hims over Wegovy pill faces legal hurdle
White House plans to launch TrumpRx Thursday
Veradermics首席执行官喜迎IPO首日股价飙升122%
Veradermics CEO has a great hair day with 122% pop in IPO
#ISC26:拜耳asundexian在III期试验中将缺血性中风风险降低26%
#ISC26: Bayer’s asundexian reduced ischemic strokes by 26% in Phase 3 trial
百时美施贵宝管线进展引关注,多项数据即将揭晓。
Bristol Myers draws pipeline excitement as several data readouts near
GLP-1药物与超级碗
GLP-1s and the Super Bowl
赛默飞世尔与查尔斯河裁员;药明康德与Vertex签订合同
Thermo Fisher, Charles River workforce cuts; WuXi signs contract with Vertex
远程医疗提供商Hims推出复方版本,挑战诺和诺德减肥药市场。
Telehealth provider Hims goes after Novo's weight loss pill with compounded version
Eikon IPO分析:大型生物科技公司估值大幅下调
Eikon IPO analysis: Big biotech names, big valuation cut
联邦贸易委员会与快捷药方就胰岛素诉讼达成和解。
FTC settles insulin lawsuit with Express Scripts
艾伯维称免疫学重磅药物将成为后修美乐时代增长"主要驱动力"。
AbbVie says immunology blockbusters will be 'main drivers' of growth post-Humira
罕见儿科PRV项目通过政府资助法重新授权至2029年。
Rare pediatric PRV program reauthorized until 2029 via government funding law
葛兰素史克新CEO聚焦更多交易与强化研发管线审查。
GSK’s new CEO eyes more dealmaking, intense pipeline inspection
Veradermics成功融资2.56亿美元IPO,用于口服落健项目。
Veradermics lands $256M IPO for oral Rogaine
Midi Health融资1亿美元,计划扩展至紧急护理与研究领域。
Midi Health raises $100M as it plans expansion into urgent care, research
Hims引入Grail癌症检测,尽管广泛使用引发疑问
Hims adds Grail's cancer test amid questions about widespread use
诺华预计仿制药将削减2026年销售额40亿美元。
Novartis says generics to erode $4B from 2026 sales
陷入困境的诺和诺德考虑收购月度GLP-1药物以强化产品组合
Embattled Novo Nordisk considers buying a monthly GLP-1 to bolster portfolio
FDA要求撤回安进公司Tavneos,公司表示不会撤药。
FDA seeks withdrawal of Amgen's Tavneos, company says it won't pull drug